Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.48 USD | -1.20% | +10.22% | -22.01% |
Jun. 04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
Financials (USD)
Sales 2024 * | 10.94M | Sales 2025 * | 10.82M | Capitalization | 20.13M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | -40M | EV / Sales 2024 * | 1.84 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.86 x |
P/E ratio 2024 * |
-0.73
x | P/E ratio 2025 * |
-1.35
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.97% |
Latest transcript on Lumos Pharma, Inc.
1 day | -1.20% | ||
1 week | +10.22% | ||
Current month | +10.22% | ||
1 month | -17.34% | ||
3 months | -18.42% | ||
6 months | -13.59% | ||
Current year | -22.01% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 2.48 | -1.20% | 5,338 |
24-06-06 | 2.51 | +6.81% | 21,716 |
24-06-05 | 2.35 | +3.52% | 4,638 |
24-06-04 | 2.27 | -1.30% | 24,129 |
24-06-03 | 2.3 | +2.22% | 10,016 |
Delayed Quote Nasdaq, June 07, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.01% | 20.13M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- LUMO Stock